Drug-resistant tuberculosis medical therapy

Jump to navigation Jump to search

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Drug-resistant tuberculosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Drug-resistant tuberculosis medical therapy

CDC on Drug-resistant tuberculosis medical therapy

Drug-resistant tuberculosis medical therapy in the news

Blogs on Drug-resistant tuberculosis medical therapy

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]; Marjan Khan M.B.B.S.[3]

Overview

Drug-resistant tuberculosis is caused by M. tuberculosis organisms that are resistant to at least one first-line anti-TB drug. Multidrug-resistant TB (MDR TB) is resistant to more than one anti-TB drug and at least isoniazid (INH) and rifampin (RIF). Treatment should be started with an empirical treatment of at least 4 drugs based on expert advice as soon as drug-resistant TB disease is suspected.

Drug-resistant tuberculosis

Type of Drug-Resistant TB

  • Rifampicin-resistant TB (RR-TB) is caused by TB bacteria that are resistant to at least rifampicin. These patients need second-line treatment similar to MDR-TB patients
  • Multidrug-resistant TB (MDR-TB) is caused by TB bacteria that are resistant to at least isoniazid and rifampicin. These patients need second-line treatment
  • Extensively drug-resistant TB (XDR-TB) is a form of MDR-TB that is also resistant to any fluoroquinolone and any of the second–line anti-TB injectable agents such as amikacin, kanamycin, or capreomycin.

Cause of Drug-Resistant TB

Drug-resistant TB can occur when the drugs used to treat TB are misused or mismanaged. Examples of misuse or mismanagement include;

  • People do not complete a full course of TB treatment
  • Health care providers prescribe the wrong treatment (the wrong dose or length of time)
  • Drugs for proper treatment are not available
  • Drugs are of poor quality

Drug-resistant TB is more common in people who:

  • Do not take their TB drugs regularly
  • Do not take all of their TB drugs
  • Develop TB disease again, after being treated for TB disease in the past
  • Come from areas of the world where drug-resistant TB is common
  • Have spent time with someone known to have drug-resistant TB disease

Multiple Drug-Resistant (MDR) Tuberculosis[1]

  • MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
  • Medical treatment for MDR-TB consists of at least 5 drugs that have shown effectiveness against MDR. Within these 5 drugs must be included at least one drug from each group.
  • Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.
  • Chronic cases with severe pulmonary disease may require more than 24 months of therapy.
  • WHO updated its treatment guidelines for drug-resistant TB in May 2016 and included a recommendation on the use of the shorter MDR-TB regimen under specific conditions.
A recommendation on the use of the shorter MDR-TB regimen[2]
  • Empirical treatment should start immediately and the regimen should be modified according to the DST (Drug susceptibility testing) results.
  • Drugs in each group must be used, in order of preference, as shown below.[3]
  • The following treatment regimens show daily dosing for each drug.

Extensively Drug-Resistant (XDR) Tuberculosis Adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed. [4]

Pretomanid

▸ Click on the following categories to expand treatment regimens.

XDR Tuberculosis

  ▸  Adults

  ▸  Children

XDR-TB Adults
Standard Regimen
Group 1: First-line oral drugs

Pyrazinamide 20–30 mg/kg
OR
Ethambutol 15–25 mg/kg
OR
Rifabutin 5 mg/kg

PLUS
Group 4:Oral bacteriostatic second-line drugs

Ethionamide 15-20 mg/kg
OR
Protionamide 15-20 mg/kg
OR
Cycloserine 10-15 mg/kg
OR
Terizidone 10-20 kg/mg
OR
Para-aminosalicylic acid 8-12 g/d divided q8-12h

PLUS
Group 5
Use at least 2 of the following:

Clofazimine 50 mg/d AND 300 mg once a month
OR
Amoxicillin/clavulanate 500 mg/125 mg q12h
OR
Linezolid 300-600 mg
OR
Imipenem 500mg q6h
OR
Clarithromycin 500-1000 mg q12h
OR
Thioacetazone 2.5 mg/kg
OR
Isoniazid (high-dose) 16–20 mg/kg

Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.[4]
XDR-TB Children
Standard Regimen
Group 1: First-line oral drugs

Pyrazinamide 20-30 mg/kg (Max: 600 mg)
OR
Ethambutol 15 mg/kg
OR
Rifabutin 5 mg/kg

PLUS
Group 4:Oral bacteriostatic second-line drugs

Ethionamide 15-20 mg/kg (Max: 1000 mg)
OR
Protionamide 15-20 mg/kg (Max: 1000 mg)
OR
Cycloserine 10-20 mg/kg (Max: 1000 mg)
OR
Terizidone 10-20 mg/kg (Max: 1000 mg)
OR
Para-aminosalicylic acid 150 mg/kg/d divided q8-12h

PLUS
Group 5
Use at least 2 of the following:

Clofazimine 50 mg/d AND 300 mg once a month
OR
Amoxicillin/clavulanate
OR
Linezolid 300-600 mg
OR
Imipenem 500mg q6h
OR
Clarithromycin 500-1000 mg q12h
OR
Thioacetazone 2.5 mg/kg
OR
Isoniazid (high-dose) 16–20 mg/kg

Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.[4] and WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children [6]

Extremely Drug-Resistant (XXDR) Tuberculosis

  • XXDR-TB or TDR-TB (totally drug resistant TB) is defined as resistance to all first-line (Group 1) and second-line (Groups 2-4) tuberculosis drugs.
  • Cases of XXDR-TB have been reported in Italy, India and Iran.[7][8][9]
  • There is no drug regimen for patients with extremely drug resistant TB that has shown successful response.

Drugs Used in Drug-Resistant Tuberculosis

  • In patients with RR-TB or MDR-TB, a regimen with at least five effective TB medicines during the intensive phase is recommended including:
    • Pyrazinamide and four core second-line TB medicines (one chosen from Group A, one from Group B, and at least two from Group C2)
    • If the minimum number of effective TB medicines cannot be composed as given above, an agent from Group D2 and other agents from Group D3 may be added to bring the total to five
  • In patients with RR-TB or MDR-TB, it is recommended that the regimen be further strengthened with high-dose isoniazid and/or ethambutol (conditional recommendation, very low certainty in the evidence).
  • It is recommended that any patient child or adult with RR-TB in whom isoniazid resistance is absent or unknown be treated with a recommended MDR-TB regimen. It could either be a shorter MDR-TB regimen, or a longer MDR-TB regimen to which isoniazid is added.
Groups Drugs
Group A

Fluoroquinolones

Group B

Second-line injectable agents

Group C

Other core second-line agents

NOTE: In children with non- severe disease Group B medicines may be excluded

Group D2

Add-on agents (not part of the core MDR-TB regimen)

Note: The WHO policy on the role of D2 agents, including their potential use in children, was under review

Group D3

Add-on agents (not part of the core MDR-TB regimen)

WHO treatment guidelines for drug- resistant tuberculosis

2016 update [10]

Medical therapy

  • 1. RR-TB or MDR-TB Tuberculosis
  • 1.1 Adult
  • Preferred regimen: At least 5 agents combination
  • 1.2 Pediatric
  • Preferred regimen: At least 5 agents combination

References

  1. WHO treatment guidelines for drug- resistant tuberculosis 2016 update. http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf?ua=1Accessed on October 14, 2016
  2. World Health Organization. THE SHORTER MDR-TB REGIMEN. http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf Accessed on October 14, 2016
  3. Caminero, José A; Sotgiu, Giovanni; Zumla, Alimuddin; Migliori, Giovanni Battista (2010). "Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis". The Lancet Infectious Diseases. 10 (9): 621–629. doi:10.1016/S1473-3099(10)70139-0. ISSN 1473-3099.
  4. 4.0 4.1 4.2 "2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition)".
  5. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C; et al. (2008). "Management of extensively drug-resistant tuberculosis in Peru: cure is possible". PLoS One. 3 (8): e2957. doi:10.1371/journal.pone.0002957. PMC 2495032. PMID 18698423.
  6. "WHO Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014" (PDF).
  7. Udwadia, Z. F.; Amale, R. A.; Ajbani, K. K.; Rodrigues, C. (2011). "Totally Drug-Resistant Tuberculosis in India". Clinical Infectious Diseases. 54 (4): 579–581. doi:10.1093/cid/cir889. ISSN 1058-4838.
  8. G. B. Migliori, G. De Iaco, G. Besozzi, R. Centis & D. M. Cirillo (2007). "First tuberculosis cases in Italy resistant to all tested drugs". Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 12 (5): E070517. PMID 17868596. Unknown parameter |month= ignored (help)
  9. Velayati, Ali Akbar (2009). "Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli". CHEST Journal. 136 (2): 420. doi:10.1378/chest.08-2427. ISSN 0012-3692.
  10. http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf?ua=1 }}